Applied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.